Stephanie Mouhat

Title: The Innovative Contributions of Stephanie Mouhat

Introduction

Stephanie Mouhat is a prominent inventor based in Chelles, France. She has made significant strides in the field of biochemistry, particularly through her work on peptide derivatives. Her innovative research has the potential to impact the treatment of autoimmune diseases.

Latest Patents

Stephanie Mouhat holds a patent for OsK1 derivatives. OsK1 is a 38-residue peptide characterized by three disulphide bridges, which is derived from the venom of scorpions. This peptide exhibits potent activity on voltage-gated K channels Kv1.1, Kv1.2, and Kv1.3, while also showing moderate activity on the type 1 intermediate-conductance Cat-activated channel K3.1. The derivatives of OsK1, particularly those involving truncation or point mutations, have been developed to enhance their activity against and selectivity for the Kv1.3 channel. This advancement positions these derivatives as promising candidates for the treatment of autoimmune diseases, including multiple sclerosis, either alone or in combination therapy with maurotoxin, another scorpion toxin.

Career Highlights

Stephanie is associated with Cellpep Pharma Inc., where she continues to push the boundaries of peptide research. Her work is characterized by a commitment to innovation and a focus on therapeutic applications.

Collaborations

Some of her notable coworkers include Jean-Marc Sabatier and Bonabes Olivier De Rouge. Their collaborative efforts contribute to the advancement of research in the field of biochemistry.

Conclusion

Stephanie Mouhat's contributions to peptide research and her innovative work on OsK1 derivatives highlight her role as a leading inventor in the field. Her research holds promise for the future of autoimmune disease treatments.